News | November 04, 2022
GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
The purpose of the conclave was to discuss the present situation of body-organ-eye donation in India and find solutions to the challenges ahead in future
Subscribe To Our Newsletter & Stay Updated
